{'52WeekChange': 0.7777778,
 'SandP52WeekChange': None,
 'address1': '24 Crosby Drive',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 8.86,
 'askSize': 2900,
 'averageDailyVolume10Day': 834675,
 'averageVolume': 990625,
 'averageVolume10days': 834675,
 'beta': 1.614565,
 'beta3Year': None,
 'bid': 8.52,
 'bidSize': 1200,
 'bookValue': -0.201,
 'category': None,
 'circulatingSupply': None,
 'city': 'Bedford',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 8.73,
 'dayLow': 8.24,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.84,
 'enterpriseToRevenue': 73.725,
 'enterpriseValue': 467709792,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '781 275 7562',
 'fiftyDayAverage': 8.166857,
 'fiftyTwoWeekHigh': 9.27,
 'fiftyTwoWeekLow': 2.46,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 46656373,
 'forwardEps': -0.42,
 'forwardPE': -20.333334,
 'fromCurrency': None,
 'fullTimeEmployees': 161,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.098900005,
 'heldPercentInstitutions': 0.50828,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/ocutx.com',
 'longBusinessSummary': 'Ocular Therapeutix, Inc., a biopharmaceutical '
                        'company, focuses on the formulation, development, and '
                        'commercialization of therapies for diseases and '
                        'conditions of the eye using its bioresorbable '
                        'hydrogel platform technology. The company markets '
                        'ReSure Sealant, a hydrogel ophthalmic wound sealant '
                        'to seal corneal incisions following cataract surgery. '
                        'Its lead product candidate is DEXTENZA (dexamethasone '
                        'ophthalmic insert), which has completed two Phase III '
                        'clinical trials for the treatment of post-surgical '
                        'ocular pain and inflammation, and allergic '
                        'conjunctivitis; and DEXTENZA, which is in Phase III '
                        'clinical trials for the treatment of dry eye '
                        'diseases. The company also develops OTX-TP '
                        '(intracanalicular travoprost insert), which is in '
                        'Phase III clinical trials for the reduction of '
                        'intraocular pressure (IOP) in patients with glaucoma '
                        'and ocular hypertension; OTX-TIC, an intracameral '
                        'travoprost implant, which is in Phase I clinical '
                        'trials for the reduction of IOP in patients with '
                        'moderate to severe glaucoma and ocular hypertension; '
                        'OTX-TKI, an intravitreal tyrosine kinase inhibitor '
                        'implant, which is in Phase I clinical trials for the '
                        'treatment of wet age-related macular '
                        'degeneration(AMD). Its various preclinical programs '
                        'include OTX- BPI for the treatment of acute ocular '
                        'pain; OTX-BDI to treat post-operative Pain, and '
                        'inflammation and bacterial infection; OTX-CSI to '
                        'treat dry-eye disease; and OTX-IVT, an intravitreal '
                        'aflibercept implant for the treatment of wet AMD and '
                        'other back-of-the-eye diseases. The company has '
                        'strategic collaboration with Regeneron '
                        'Pharmaceuticals, Inc. (Regeneron) for the development '
                        "and commercialization of products using the Company's "
                        'sustained-release hydrogel in combination with '
                        "Regeneron's large molecule VEGF-targeting compounds "
                        'for the treatment of retinal diseases. Ocular '
                        'Therapeutix, Inc. was founded in 2006 and is '
                        'headquartered in Bedford, Massachusetts.',
 'longName': 'Ocular Therapeutix, Inc.',
 'market': 'us_market',
 'marketCap': 536084832,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_41955650',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -90760000,
 'nextFiscalYearEnd': 1640908800,
 'open': 8.67,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '781 357 4000',
 'previousClose': 8.64,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 84.502655,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 8.73,
 'regularMarketDayLow': 8.24,
 'regularMarketOpen': 8.67,
 'regularMarketPreviousClose': 8.64,
 'regularMarketPrice': 8.67,
 'regularMarketVolume': 410214,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 62773400,
 'sharesPercentSharesOut': 0.0937,
 'sharesShort': 5881397,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 5448440,
 'shortName': 'Ocular Therapeutix, Inc.',
 'shortPercentOfFloat': 0.1071,
 'shortRatio': 5.97,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'OCUL',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.903,
 'twoHundredDayAverage': 6.104712,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'b2e86f5b-6ae3-30af-bdc2-4b9ad5a2cf9e',
 'volume': 410214,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.ocutx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '01730'}